- $13.99m
- -$9.75m
- $65.30m
- 46
- 45
- 42
- 40
Annual income statement for MEI Pharma, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
R2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K/A | 10-K/A | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 27.8 | 34.8 | 40.7 | 48.8 | 65.3 |
| Cost of Revenue | |||||
| Gross Profit | 25.1 | 33.4 | 40.7 | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 53.5 | 95.2 | 116 | 85.6 | 50.8 |
| Operating Profit | -25.7 | -60.4 | -75.5 | -36.8 | 14.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -47.2 | -41.3 | -54.5 | -31.8 | 17.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -47.2 | -41.3 | -54.5 | -31.8 | 17.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -47.2 | -41.3 | -54.5 | -31.8 | 17.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -47.2 | -41.3 | -54.5 | -31.8 | 17.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -10.3 | -7.34 | -8.75 | -4.78 | 4.3 |
| Special Dividends per Share |